Efferon Targets Pediatric Sepsis With Multimodal Blood Purification
AI-generated image · Bay Street Wire
The startup is expanding its reach into 30 countries with a device designed to filter both endotoxins and cytokines in children.
Efferon is attempting to reduce childhood mortality associated with sepsis, a condition that, as TechCrunch first reported, claims approximately 3 million children under five years old every year. The company has developed a medical device designed to accelerate recovery and lower organ failure rates by filtering the blood to remove toxins when antibiotics are insufficient to stop the immune system's overreaction.
According to Efferon CEO and co-founder Dima Romashin, the company's technology differs from existing market options by utilizing a mechanism capable of absorbing both cytokines and endotoxins simultaneously. While the company produces absorbers for adults, it has developed Efferon NEO specifically for pediatric patients to account for their lower circulating blood volume.
TechCrunch reports that Efferon NEO received a CE mark in April, making it the first multimodal blood purification device engineered specifically for pediatric sepsis. The device is currently utilized in intensive care units across 30 countries, including Thailand, Saudi Arabia, and European hospitals.
The technology was originally created by scientists at Moscow State University, including Efferon co-founder Ivan Bessonov. The company is currently preparing for an FDA approval filing and expects to reach $2 million in annualized revenue by the end of 2026.